FC
GNMK

Fairpointe Capital’s GenMark Diagnostics, Inc GNMK Stock Holding History

Fairpointe Capital’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-52,658
Closed -$387K – 88
2018
Q3 		$387K Hold
52,658
– – 0.01% 69
2018
Q2 		$336K Hold
52,658
– – 0.01% 71
2018
Q1 		$286K Hold
52,658
– – 0.01% 75
2017
Q4 		$220K Buy
+52,658
New +$317K ﹤0.01% 79

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fairpointe Capital's GNMK Position: Q4 2018 in Review

Fairpointe Capital sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2018, closing a stake of 52,658 shares — an estimated $387K sold.

Fairpointe Capital first reported a position in GNMK in Q4 2017 and held it in 4 quarters. The position peaked at $387K in Q3 2018. 103 funds tracked by Wall St. Rank hold GNMK as of Q4 2018.

  • Fairpointe Capital reported no remaining GenMark Diagnostics, Inc position as of Q4 2018 after selling out during the quarter.
  • Fairpointe Capital sold 52,658 GenMark Diagnostics, Inc shares in Q4 2018, an estimated $387K.
  • Fairpointe Capital first reported a position in GenMark Diagnostics, Inc in Q4 2017 and held it in 4 quarters.
  • Fairpointe Capital's GenMark Diagnostics, Inc position peaked at $387K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2018.

Based on Fairpointe Capital's 13F filing for Q4 2018, filed 14 Feb 2019.